2025 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board OnDemand
(5)
Image For Activity Cover
Availability
On-Demand
4 Courses
Cost
$0.00
Credit Offered
4 CME (AMA) Credits
4 CME (Other) Credits

2025 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Date of Release: February 3, 2025
Expiration Date: February 3, 2027 
Estimate time of completion: 8 hours

Course Description
This course explores the clinical significance of germline and somatic variants in cancer and provides practical knowledge on the application of clinical guidelines and bioinformatics tools for treatment recommendations. Participants will gain an understanding of how various disciplines—medical oncology, molecular pathology, genomics, bioinformatics, and genetic counseling—collaborate in cancer care. Emphasizing the importance of multi-institutional collaboration, the course covers workflows for cancer variant interpretation, including the utilization of genomic tumor boards and variant annotation pipelines.

Target Audience
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia. 

Webinar Series

January 28, 2025 
Title: Cases in Precision Oncology: Highlights from the 2024 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

February 25, 2025 
Title: Chromosomal Mimicry in Hematologic Malignancies

March 25, 2025 
Title: Complementary Use of Circulating Tumor Cell Sequencing and Tumor Sequencing

May 27, 2025
Title: Longitudinal Analysis in a Case of Langerhans Cell Histiocytosis 

June 24, 2025
Title: Cases in Precision Oncology: Complex In-frame DELINS in Cancer 


Learning Objectives
At the conclusion of this series, participants should be able to:
•    Apply clinical guidelines and bioinformatics tools to determine the clinical significance of germline and somatic variants in cancer  
•    Describe the spectrum of resources to aid in cancer variant interpretation in the clinic
•    Utilize genomic tumor boards informed by multiple workflows and annotation pipelines

no image

Manuela Benary, PhD

Bioinformatician

Charité – Universitätsmedizin Berlin, Berlin, Germany

 

no image

 

Beth Pitel, MS

Clinical Variant Scientist – Oncology

Assistant Professor of Laboratory Medicine and Pathology

Mayo Clinic

Jason Saliba, PhD

Senior Scientist at Washington University School of Medicine in St. Louis

 



no image

 

Adrian Dubuc, PhD, FACMG
Vice-Chair, Cytogenetics/Genomics Clinical Research
Director, Clinical Cytogenetics Laboratory 
Roswell Park Comprehensive Cancer Center

Valentina Nardi, MD
Associate Professor of Pathology – Massachusetts General Hospital

 

Amir T. Fathi, MD
Associate Professor of Medicine – Massachusetts General Hospital

Gabriela S. Hobbs, MD
Associate Professor of Medicine – Massachusetts General Hospital 

Scott T. Ryall, PhD
Associate Pathologist – Brigham and Women’s Hospital 
Instructor in Pathology – Harvard Medical School

Melissa M. Zhao, MD
Clinical Fellow in Pathology – Brigham and Women’s Hospital


no image

Nisha Kanwar, PhD
Laboratory Genetics and Genomics Fellow, Mayo Clinic
Department of Laboratory Medicine and Pathology


no image

Damian Rieke, MD

Spokesperson for the Platform for Personalized Cancer Medicine - Charité

Charité – Universitätsmedizin Berlin, Berlin, Germany

no image

Markus Möbs, PhD

Molecular Biologist

Charité – Universitätsmedizin Berlin, Berlin, Germany

 

 

 


Planning Committee:
Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP
Claudia Barnett

AMA PRA Category 1 CreditsTM & CME Other

Accreditation
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

Claiming your Educational Credits
This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Learner Data Consent
ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission. 

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

 

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

 

All of the relevant financial relationships listed for these individuals have been mitigated.

 

Name

Role: Presenter/ Panelist / Moderator / Liaison / Planner / Peer Reviewer

Financial Disclosure for 24 Months (relationship is ongoing)

Claudia Barnett

Staff

Nothing to Disclose

Manuela Benary, PhD

Planner/Moderator

Speaker: Novartis

Adrian Dubuc, PhD, FACMG

Presenter

Nothing to Disclose

Amir Fathi, MD

Presenter

 

Consultant: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Autolus, Bristol-Myers Squibb, Daiichi Sankyo Co, Genentech, Gilead Sciences Inc., Ipsen Biopharmaceuticals, Inc., Kite Pharma. Inc. Kura Oncology, Menarini Group, Novartis, Orum, Pfizer, Prelude Therapeutics, Remix, Rigel Pharmaceuticals, Inc., Schrodinger, Servier Pharmaceuticals LLC, Syndax, Takeda Oncology

Grant: Abbvie, Servier Pharmaceuticals LLC

Gabriela Hobbs, MD

Presenter

Consultant: Abbvie. Bristol Myers Squibb, GlaxoSmithKline, Novartis, PharmaEssentia, Sobi Research: Incyte Corporation

Nisha Kanwar, PhD

Presenter

Nothing to Disclose

Gordana Raca, MD, PhD, FACMG

Planner

Nothing to Disclose

Jane Radford, MHA, CHCP

Staff

Nothing to Disclose

Beth Pitel, MS

Planner

Somatic Advisory Board: Qiagen

Jason Saliba, PhD

Planner

Nothing to Disclose

Damian Rieke, MD

Presenter

Consultant: Bayer; BeiGene, Ltd.; Eli Lilly and Company; Johnson and Johnson; Servier Pharmaceuticals

Markus Möbs, PhD

Presenter

Nothing to Disclose

Valentina Nardi, MD

Presenter

Nothing to Disclose

Scott Ryall PhD

Presenter

Nothing to Disclose

Melissa Zhao, MD

Presenter

Nothing to Disclose

 

Disclaimer

ACMG educational programs are designed primarily as an educational tool for healthcare professionals who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare professionals should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net

© 2025 American College of Medical Genetics and Genomics. All rights reserved.

Powered By